Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftobiprole medocaril - Basilea Pharmaceutica

X
Drug Profile

Ceftobiprole medocaril - Basilea Pharmaceutica

Alternative Names: BAL-5788; BAL-9141; Ceftobiprole; Ceftobiprole medocaril sodium; JNJ-30982081; Mabelio; RO-65-5788; Zeftera; ZEVTERA; Zevtera

Latest Information Update: 20 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Avir Pharma; Basilea Pharmaceutica; Department of Health & Human Services; Hikma Pharmaceuticals; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development; Knight Therapeutics; Shenzhen China Resources Gosun Pharmaceutical
  • Class Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bacteraemia; Community-acquired pneumonia; Skin and soft tissue infections

Highest Development Phases

  • Marketed Community-acquired pneumonia; Nosocomial pneumonia
  • Registered Bacteraemia; Skin and soft tissue infections
  • Phase III Bacterial infections
  • No development reported Paediatric infections

Most Recent Events

  • 03 Apr 2024 Zevtera receives priority review status for Community-acquired pneumonia, skin and soft tissue infections and Staphylococcus aureus infections in USA before April 2024
  • 03 Apr 2024 Eficacy data from a phase III trial for Community-acquired pneumonia released by Basilea Pharmaceutica
  • 03 Apr 2024 Eficacy data from a phase III trial for Skin and soft tissue infections released by Basilea Pharmaceutica
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top